Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily

被引：0
|
作者：
Le Coutre, P. [1 ]
Shah, N. [2 ]
Cortes, J. E. [3 ]
Schiffer, C. [4 ]
Bahceci, E. [5 ]
Lambert, A. [6 ]
Saglio, G. [7 ]
机构：
[1] Charite Campus Virchow Klinikum, Berlin, Germany
[2] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Commun, San Francisco, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Hudson Webber Canc Res Ctr, Detroit, MI USA
[5] Bristol Myers Squibb Co, Plainsboro, NJ USA
[6] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[7] Osped San Luigi Gonzaga, Div Med Interna & Ematol, Lab Med & Oncol Mol, Turin, Italy
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [1] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    le Coutre, P.
    Bahceci, E.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Bixby, Dale L.
    Flinn, Ian
    O'Hare, Thomas J.
    Hu, Simin
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W. N.
    Mauro, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [4] Five-year follow-up of patients with imatinib-resistant or - intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    Guilhot, F.
    Brummendorf, T. H.
    Chen, A. C.
    Healey, D.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] FOUR-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING DASATINIB: EFFICACY AND SAFETY
    Huang, X.
    Hu, J.
    Li, J.
    Jin, J.
    Meng, F.
    Shen, Z.
    Liu, T.
    Wu, D.
    Wang, J.
    Wang, J.
    HAEMATOLOGICA, 2014, 99 : 331 - 332
  • [6] Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W.
    Mauro, Michael J.
    BLOOD, 2014, 124 (21)
  • [7] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
  • [8] Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Liu, Delong
    Matloub, Yousif
    Mulchopadhyay, Jaydip
    Liu, David
    Goldberg, Stuart L.
    BLOOD, 2008, 112 (11) : 741 - 741
  • [9] Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kim, Dong-Wook
    Shah, Neil P.
    Mayer, Jiri
    Rowlings, Philip
    Nakamae, Hirohisa
    Bradley-Garelik, M. Brigid
    Mohamed, Hesham
    Kantarjian, Hagop M.
    Saglio, Giuseppe
    BLOOD, 2013, 122 (21)
  • [10] Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
    Shah, Neil P.
    Kantarjian, Hagop
    Kim, Dong-Wook
    Hochhaus, Andreas
    Saglio, Giuseppe
    Guilhot, Francois
    Schiffer, Charles Alan
    Steegmann, Juan Luis
    Mohamed, Hesham
    Dejardin, David
    Healey, Diane I.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345